epratuzumab
A recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells. After binding to CD22, epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC).
| Synonym: | AMG 412 |
|---|---|
| US brand name: | LymphoCide |
| Abbreviation: | hLL2 |
| Code name: | IMMU-HLL2 |